Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to compare the medication adherence measured by PDC of patients with FDC or double-pill combination therapy in real-world Japanese therapeutic practice.The further objective of this study is how much influence the background of patients to the adherence.

Official Title
-----------------
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: subjects treated with telmisartan/hydrochlorothiazide
* Drug: Subjects treated with Telmisartan and amlodipine
* Drug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
* Drug: subjects treated with telmisartan+amlodipine double pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hypertension Patients must have their first prescription (defined as index date*) for telmisartan and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010 Patients must have their first prescription (defined as index date*) for telmisartan and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011 Patients must have at least 180 days follow up verified by the presence of prescription record Exclusion Criteria: Patients who were under 40 years old at the time of enrolment Patients who prescribed the study drugs less than 90 days during a follow up period of 180 days Patients whose visits are less than 2 times during a follow up period of 180 days

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Telmisartan and hydrochlorothiazide group<br> | Drug: subjects treated with telmisartan/hydrochlorothiazide<br>* subjects treated with telmisartan/hydrochlorothiazide<br>* Other names: MICARDIS, PRITOR, TELMISARTAN;|
| Telmisartan and amlodipine group<br> | Drug: Subjects treated with Telmisartan and amlodipine<br>* Subjects treated with Telmisartan and amlodipine<br>* Other names: MICARDIS, PRITOR, TELMISARTAN;|
| Telmisartan+hydrochlorothiazide double-pill combination group<br> | Drug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group<br>* subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group<br>* Other names: MICARDIS, PRITOR, TELMISARTAN;|
| telmisartan+amlodipine double-pill combination group<br> | Drug: subjects treated with telmisartan+amlodipine double pill<br>* subjects treated with telmisartan+amlodipine double pill<br>* Other names: MICARDIS, PRITOR, TELMISARTAN;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of days covered of patients treated with single- and double- combination therapy |  | 180 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic and clinical characteristics of patients treated with single- and double combination |  | 180 days |